fight disease
Question:
What s the likelihood of experiencing a major health event (excluding mortality) for individuals aged 40 and older?
ChatGPT:
Here’s a cumulative summary of the likelihood of experiencing a major health event (excluding mortality) for individuals aged 40 and older:
40: 60-70% (cardiovascular disease, cancer, other chronic conditions).
50: 80-85% (heart disease, diabetes, arthritis, cancer).
60: 90-95% (chronic diseases, dementia, osteoporosis).
70: 98-99% (dementia, frailty, falls, multiple chronic conditions).
80+: Approaches 100% (severe chronic conditions, frailty, dementia).
(see FIGHT DISEASE DETAILS* below)
Question:
I am in remission after having Multiple Myeloma cancer. Is this cancer type curable?
ChatGPT:
Multiple myeloma is generally considered a treatable but not a curable disease.
Question:I’ve been in remission for a little over two years. How much longer can I expect to stay in remission?
ChatGPT:
As of the latest data available from sources like the American Cancer Society, the five-year relative survival rate for multiple myeloma is approximately 55.6%. The ten-year rate is approximately 33.9%.
My Conclusion:
Since I’ve been in remission for 2 1/2 years, the chance me staying in remission for the next 2 1/2 years is is a little over 50-50. The chance that I make it for the next 7 1/2 years is one 1 out of 3. Understand: And I don’t say this lightly, I’m not going back to the treatments if and when I come out of remission. I’m not going back to that bed and put my wife what she had to go through to keep me alive. I’m not alone in my feeling toward this. Many people won’t go back to the treatments a second time. I am literally fighting for my life. Again, what am I going to do, not spend the money and die a little bit richer?
Observation:
So, why do I feel that these infusions have helped me with my health and possibly give me better odds of staying in remission than I would have otherwise? Again, I will use ChatGPT to answer the questions.
Question:
Is this statement true: Stem cells are a vital part of our body's system, and one of their key functions is to produce the cells that make up our immune system, which fights disease.
ChatGPT:
Yes, stem cells are indeed critical to the body's ability to produce immune cells, which are directly involved in fighting disease.
Question:
Is it possible that stem cells, taken from a baby’s cord blood, can be used to supplement a another person’s stem cells?
ChatGPT:
Yes, stem cells from a baby’s cord blood can indeed be used to supplement or replace another person’s stem cells, and this approach has been successfully used in various medical treatments. This process is known as a cord blood transplant or hematopoietic stem cell transplant (HSCT).
Question:
Do these transplanted stem cells have the same ability to produce the cells that make up our immune system as a person’s own stem cells.
ChatGPT:
Yes, transplanted stem cells, such as those from cord blood, have the same ability to produce the cells that make up the immune system as a person's own stem cells.
Question:
Can you give me specific examples of: Studies, clinical trials, or expert opinions on using cord blood stem cells to support remission.
ChatGPT:
Recent advancements in stem cell therapy, particularly involving cord blood-derived cells, have shown promise in supporting remission for multiple myeloma patients. Here are some notable studies and expert opinions:
1. Omidubicel Approval for Blood CancersIn April 2023, the U.S. Food and Drug Administration (FDA) approved Omidubicel (brand name Omisirge), a novel cord blood-derived cellular therapy, for patients with high-risk blood cancers, including leukemia and lymphoma. This approval was based on a multicenter international phase 3 clinical trial led by Dr. Mitchell Horwitz of the Duke Cancer Institute. Omidubicel is the first modified allogeneic umbilical cord blood-based stem cell transplant product to receive Breakthrough Therapy designation from the FDA.
2. ECT-001 (UM171) Expanded Cord Blood in Multiple MyelomaA clinical trial (NCT03441958) is investigating the use of ECT-001 expanded cord blood stem cells in patients with newly diagnosed multiple myeloma. Participants receive a reduced-intensity conditioning allogeneic hematopoietic stem cell transplant with ECT-001 expanded cord blood after initial induction treatment and autologous stem cell transplant. This study aims to evaluate the safety and efficacy of this approach in enhancing remission.
3. Umbilical Cord Blood-Derived Natural Killer CellsA phase II trial (NCT01729091) is examining the combination of umbilical cord blood-derived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan, followed by autologous stem cell transplantation in patients with high-risk multiple myeloma. This study aims to assess the safety and efficacy of this combination therapy in improving patient outcomes.
4. Expert Opinion on Cord Blood TransplantationA study published in Haematologica analyzed outcomes of unrelated cord blood transplantation in patients with multiple myeloma and plasma cell leukemia. The research suggests that, although not standard, cord blood transplantation can be a viable option for certain patients, especially when traditional donor matches are unavailable.
These examples highlight the ongoing research and clinical interest in utilizing cord blood-derived stem cells and immune cells to support remission and improve outcomes in multiple myeloma patients. While promising, these therapies are still under investigation, and further studies are needed to establish their efficacy and safety fully.
My Conclusion:
While it’s not a sure thing that using stem cell therapy will keep me in remission from multiple myeloma cancer, it has great promise to do so. Like I said before, “I’ll do anything to stay out of that bed and keep my wife from going through what she had to do to keep me alive”.
Again, if I didn't have the money, I would borrow it and find a way to pay it back later. I can make more money, but I can't make more time!
If I'm wrong, well it won't be the first time!
Hopefully, the stem cell therapy will help keep me in remission. But if it doesn’t, and my cancer comes back, at least I have had over a wonderful year of vitality. At 81 years of age, it's like I am 40 again! Recently I convinced Debbie, my wife, to start her long-term program at my expense. I did this because there’s nobody else I’d rather be with than her.
____________________
*FIGHT DISEASE DETAILS
Request:
List major health issues that an individual may get in their lifetime and the percentages of those individuals.
ChatGPT:
Here’s a summary of major disease types with approximate cumulative percentages:
1. Cardiovascular Diseases: 50% (heart disease, stroke, hypertension).
2. Cancers: 40% (any type of cancer).
3. Metabolic and Endocrine Disorders: 40%-50% (diabetes, obesity, thyroid disorders).
4. Neurological and Cognitive Disorders: 25%-30% (Alzheimer’s, Parkinson’s, other dementias).
5. Respiratory Diseases:10%-15% (COPD, asthma, pulmonary fibrosis).
6. Musculoskeletal Disorders: 50%-60% (arthritis, osteoporosis, chronic back pain).
7. Mental Health Disorders: 20%-25% (depression, anxiety, substance use).
8. Digestive and Gastrointestinal Conditions: 20%-30% (GERD, IBS, and diverticulitis).
9. Kidney and Urinary Disorders: 15%-20% (CKD, incontinence, prostate issues).
10. Vision and Hearing Loss: 50%-60% (cataracts, macular degeneration, hearing loss).
11. Infectious Diseases: 30%-40% (pneumonia, influenza, shingles).
12. Blood Disorders: 10%-20% (anemia blood clots).
13. Skin Conditions: 20% (skin cancer chronic wounds).
14. Autoimmune Diseases: 1%-3% (lupus, multiple sclerosis).
Request:
For each type, discuss the ability of Stem cell therapy, from a baby's cold blood, to mitigate these problems and the science behind it.
ChatGPT:
Stem cell therapy, particularly from cord blood, is a growing field of regenerative medicine. Cord blood contains hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs), which have unique properties for repairing tissues and modulating immune responses. Below is a discussion of how stem cell therapy could mitigate various major disease types and the science behind it:
1. Cardiovascular Diseases (~50%)
• Potential Impact:
• Stem cells (especially MSCs) have been shown to repair heart tissue by stimulating angiogenesis (new blood vessel growth), reducing inflammation, and regenerating damaged myocardium after a heart attack.
• Cord blood-derived MSCs can help reverse cardiac fibrosis and improve heart function in conditions like heart failure.
• Scientific Basis:
• MSCs secrete growth factors like VEGF and HGF, which promote tissue repair and reduce oxidative stress.
• Clinical trials show moderate success in improving heart function after ischemic damage.
2. Cancers (~40%)
• Potential Impact:
• Stem cells are primarily used in cancer treatment for bone marrow replacement after chemotherapy or radiation, particularly in blood cancers like leukemia and lymphoma.
• Research is ongoing to use stem cells to deliver anti-cancer agents directly to tumors.
• Scientific Basis:
• Hematopoietic stem cells (HSCs) from cord blood are routinely used in bone marrow transplants to rebuild the immune system.
• MSCs can modulate the immune response, potentially reducing tumor growth, though this is still under investigation.
3. Metabolic and Endocrine Disorders (~40%-50%)
• Potential Impact:
• In type 1 diabetes, cord blood-derived stem cells show promise in regenerating insulin-producing beta cells.
• MSCs reduce inflammation and may help improve insulin sensitivity in type 2 diabetes.
• Scientific Basis:
• MSCs regulate immune activity and repair pancreatic tissue through paracrine signaling.
• Clinical trials have shown reduced insulin dependence in some patients treated with cord blood stem cells.
4. Neurological and Cognitive Disorders (~25%-30%)
• Potential Impact:
• Cord blood-derived stem cells may promote neural regeneration in Alzheimer’s, Parkinson’s, and stroke recovery.
• MSCs can cross the blood-brain barrier and reduce neuroinflammation, a key factor in neurodegenerative diseases.
• Scientific Basis:
• MSCs secrete neurotrophic factors (e.g., BDNF) that encourage neuron survival and regeneration.
• Preclinical studies show promise in improving cognitive and motor functions in animal models.
5. Respiratory Diseases (~10%-15%)
• Potential Impact:
• MSCs from cord blood have been tested for conditions like COPD and pulmonary fibrosis with encouraging results.
• They help by reducing lung inflammation and fibrosis while promoting alveolar repair.
• Scientific Basis:
• MSCs release anti-inflammatory cytokines and growth factors that repair epithelial tissue and reduce scar formation.
• Studies have shown improved lung function in animal models and early-phase human trials.
6. Musculoskeletal Disorders (~50%-60%)
• Potential Impact:
• MSCs are being used to treat osteoarthritis by regenerating cartilage and reducing inflammation.
• They also show potential in treating osteoporosis by enhancing bone regeneration.
• Scientific Basis:
• MSCs differentiate into chondrocytes (cartilage cells) and osteoblasts (bone cells), promoting repair.
• Clinical trials show reduced pain and improved joint function in arthritis patients treated with stem cells.
7. Mental Health Disorders (~20%-25%)
• Potential Impact:
• MSCs may help reduce inflammation in the brain, which is implicated in depression and anxiety.
• Preclinical studies suggest potential for treating PTSD and neuropsychiatric conditions by promoting neural repair.
• Scientific Basis:
• MSCs secrete neuroprotective and anti-inflammatory factors like IL-10, reducing neuroinflammation linked to mental health issues.
• Research is still in early stages for mental health applications.
8. Digestive and Gastrointestinal Conditions (~20%-30%)
• Potential Impact:
• MSCs have shown potential in treating inflammatory bowel disease (IBD) by reducing gut inflammation and promoting tissue repair.
• They may also help in treating liver fibrosis and other gastrointestinal damage.
• Scientific Basis:
• MSCs modulate immune responses in the gut and secrete factors that encourage regeneration of intestinal lining.
• Clinical trials have shown promise in reducing symptoms of Crohn’s disease and ulcerative colitis.
9. Kidney and Urinary Disorders (~15%-20%)
• Potential Impact:
• Stem cells can slow or reverse chronic kidney disease by regenerating renal cells and reducing inflammation.
• They may help repair bladder damage in incontinence and other urinary disorders.
• Scientific Basis:
• MSCs promote angiogenesis in kidney tissues, reducing fibrosis and enhancing renal function.
• Preclinical models show improved renal function after MSC therapy.
10. Vision and Hearing Loss (~50%-60%)
• Potential Impact:
• Cord blood stem cells are being explored for retinal repair in macular degeneration and diabetic retinopathy.
• Stem cells may also help regenerate damaged auditory hair cells in hearing loss.
• Scientific Basis:
• MSCs secrete growth factors that encourage retinal and auditory cell repair.
• Early studies show improvements in vision and hearing in animal models.
11. Infectious Diseases (~30%-40%)
• Potential Impact:
• MSCs show promise in treating complications from severe infections like sepsis or COVID-19 by modulating the immune response.
• They may help repair lung damage from infections like pneumonia.
• Scientific Basis:
• MSCs release anti-inflammatory cytokines and growth factors that reduce systemic inflammation.
• Clinical trials have shown reduced mortality in sepsis patients treated with MSCs.
12. Blood Disorders (~10%-20%)
• Potential Impact:
• HSCs from cord blood are already widely used to treat leukemia, lymphoma, and other blood cancers.
• MSCs may help treat anemia and clotting disorders by regenerating bone marrow.
• Scientific Basis:
• HSCs differentiate into all blood cell types, rebuilding the hematopoietic system after damage.
• Proven in clinical practice for bone marrow transplantation.
13. Skin Conditions (~20%)
• Potential Impact:
• MSCs are being explored for wound healing and skin regeneration, including for chronic ulcers and burns.
• Scientific Basis:
• MSCs accelerate wound healing by promoting angiogenesis and reducing inflammation.
• Clinical trials show faster healing times and improved outcomes in patients with chronic wounds.
14. Autoimmune Diseases (~1%-3%)
• Potential Impact: MSCs can regulate overactive immune responses in autoimmune conditions like lupus and multiple sclerosis.
• Scientific Basis: MSCs suppress pro-inflammatory T cells and promote regulatory T cells, reducing autoimmune damage.
• Studies show improved symptoms and reduced relapse rates in autoimmune disease patients.
Key Limitations: While stem cell therapy holds great promise, many treatments are still in experimental or early clinical stages. Challenges include ensuring safety, avoiding immune rejection, and achieving consistent efficacy. Ongoing research and clinical trials are crucial for fully realizing its potential.
____________________
STEM CELL THERAPY, INC.
LEGACY DONORS TO:
MD Anderson, Houston &
Keels & Wheels, Seabrook